Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TCM Draft For Health Care Reform Unveiled

This article was originally published in PharmAsia News

Executive Summary

China State Administration of Traditional Chinese Medicine has completed the basic draft of "Opinion on supporting and promoting TCM development." The document, as one of the components in China's heath care reform, specifies TCM's important role ranging from guiding principles to implementing concepts. In particular, it addresses issues on rural TCM work, compensation mechanisms and TCM practicing laws. In addition, the Ministry of Health has asked TCM administrative departments to accord as much emphasis on TCM as Western medicine by promoting TCM reform, accelerating legislation and strengthening talent cultivation. (Click here for more - Chinese Language)

You may also be interested in...



Advanced Imaging Group Calls For Swifter FDA Approvals For Mobile X-Ray, CT, Ultrasound Devices For COVID-19 Crisis

The Medical Imaging & Technology Alliance (MITA) recently sent a letter to the US FDA recommending steps the agency can take to help the advanced imaging industry quickly respond to the COVID-19 outbreak.

ACC 2020: TAVR Matches Surgery In Two-Year PARTNER 3 Results

The two-year results from the PARTNER 3 trial showed transcatheter aortic valve replacement with Edwards Lifesciences' Sapien 3 system was statistically non-inferior to surgical valve replacement in low-risk patients. The one-year results from the trial had shown TAVR was superior to surgery in low-risk patients.

Individualized Therapeutics Could Get Boost From NIH Platform Gene Therapy Pilot

Experience and data from the study, which will use the same vector platform to deliver different transgenes for different diseases, could feed into the US FDA’s efforts to establish a public-private partnership to enable manufacturing of gene therapies for ultra-rare diseases.

UsernamePublicRestriction

Register

SC071058

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel